SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study
Primary result · Skeletal muscle FA uptakeResult — go to the resultDifference (least square means) 1.0 μmol ⋅ 100 g-1 ⋅ min-1 95% CI 0.07–2.0Authors' conclusion
Six weeks of treatment with dapagliflozin increases skeletal muscle and brain FA uptake, partly driven by a rise in free FA availability. This finding is in accordance with previous indirect measurements showing enhanced FA metabolism in response to SGLT2 inhibition and extends the notion of a shift toward increased FA use to muscle and brain.
Study context
- Population
- Patients with T2D treated with metformin38 completed
- Participants
- 53 patients
- Comparison
- Dapagliflozin 10 mg daily vs placebo, 6 weeks
- Dapagliflozinn = 21
- Placebon = 17reference
- Primary endpoint
- Tissue FA uptake (skeletal muscle, brain, small intestine, subcutaneous and visceral adipose tissue) by PET
- Follow-up
- 6 weeks
Methodological detailsdouble-blind, placebo-controlled, positron emission tomography (PET) study, Treatment effects assessed by ANCOVA; least square means and 95% CIs for between-group difference
- Double-blind
- Placebo-controlled
- PET study
- Treatment effects assessed by ANCOVA; least square means and 95% CIs for between-group difference
Primary result
Skeletal muscle FA uptake
Difference (least square means)
1.0 μmol ⋅ 100 g-1 ⋅ min-1
95% CI 0.07–2.0
P = 0.032
Dapagliflozinvs Placebo
difference (least square means) 1.0 μmol ⋅ 100 g-1 ⋅ min-1 (95% CI 0.07–2.0); P = 0.032
As reported in the abstract
Further findings
| Outcome | Difference (least square means) (μmol ⋅ 100 g-1 ⋅ min-1) (95% CI) | P value | |
|---|---|---|---|
| Whole-brain FA uptake · 6 weeks | 0.10 (0.02–0.17) | P = 0.01 | |
| −0.100.10.2Difference, μmol ⋅ 100 g-1 ⋅ min-1 (linear scale) |
Whole-brain fatty acid (FA) uptake · 6 weeks
- Effect observed in both gray and white matter regions
Original publication
SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study. Diabetes Care. Published 28 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →